Myocarditis results from inflammation of the myocardium that can be triggered by a range of underlying mechanisms. Viral pathogens, particularly enteroviruses and other cardiotropic viruses, represent a recognized class of infectious triggers. Other infectious agents, autoimmune conditions, and toxic or hypersensitivity exposures may also precipitate myocardial inflammation. The current knowledge packet does not catalogue specific causative genes, and no heritable Mendelian inheritance pattern is defined for this condition; myocarditis is primarily an acquired inflammatory process rather than a genetic or inherited disorder.

Diagnosis of myocarditis incorporates clinical presentation, electrocardiographic findings, imaging, and laboratory markers of myocardial injury and systemic inflammation. Cardiac MRI has become an important non-invasive diagnostic modality, enabling tissue characterization of myocardial edema and fibrosis. In selected cases, endomyocardial biopsy provides histopathological confirmation of inflammatory infiltration. Echocardiography assesses cardiac function and structural changes. The current knowledge packet does not enumerate specific validated diagnostic criteria thresholds for this condition.

No treatments are specifically approved for myocarditis in the current knowledge packet. Management is directed at identifying and addressing the underlying cause when one is identified and at supporting cardiac function during the acute inflammatory phase. Supportive care approaches address hemodynamic stability and prevention of complications arising from myocardial dysfunction. The treatment landscape continues to be investigated, with ongoing clinical studies examining novel therapeutic strategies for acute and chronic myocarditis. The sole agent listed in orphan drug records (Indium In 111 murine monoclonal antibody FAB to myosin) holds withdrawn status and is not currently available.

The clinical course of myocarditis is variable. Many individuals with mild presentations experience full or near-full cardiac recovery. Others may develop persistent myocardial dysfunction, evolving to dilated cardiomyopathy or chronic heart failure over time. Severe acute cases can be life-threatening, and a subset of affected individuals require advanced cardiac support or transplantation. Individual outcomes depend on the severity and duration of the initial inflammatory episode, the underlying etiology, and the degree of residual myocardial injury.

Myocarditis is the subject of active clinical investigation, with numerous registered clinical trials at ClinicalTrials.gov examining diagnostic approaches, therapeutic interventions, and disease mechanisms. Research spans acute presentations as well as chronic sequelae including inflammatory cardiomyopathy. Studies address a range of potential etiologies and therapeutic targets, reflecting the heterogeneous nature of the condition. Investigations are conducted across academic medical centers and include diverse patient populations and disease presentations.